Neuroblastoma is an indication for drug development with over 170 pipeline drugs currently active. According to GlobalData, preregistered drugs for Neuroblastoma have a 80% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Neuroblastoma compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Neuroblastoma overview
Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest, or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands before spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include a lump in the abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes, and difficulty with movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, or urine test. It may be controlled by chemotherapy, radiation therapy, stem cell transplant, and medication such as monoclonal antibody regimens.
For a complete picture of PTSR and LoA scores for drugs in Neuroblastoma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.